BR0112286A - Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (cns); composto; sua composição farmacêutica; uso e método para tratamento - Google Patents

Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (cns); composto; sua composição farmacêutica; uso e método para tratamento

Info

Publication number
BR0112286A
BR0112286A BR0112286-0A BR0112286A BR0112286A BR 0112286 A BR0112286 A BR 0112286A BR 0112286 A BR0112286 A BR 0112286A BR 0112286 A BR0112286 A BR 0112286A
Authority
BR
Brazil
Prior art keywords
treatment
disorders
cns
compound
pharmaceutical composition
Prior art date
Application number
BR0112286-0A
Other languages
English (en)
Inventor
Benny Bang-Andersen
Jakob Felding
Jan Kehler
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR0112286A publication Critical patent/BR0112286A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE INDOL úTEIS PARA O TRATAMENTO DE DISTúRBIOS DO SISTEMA NERVOSO CENTRAL (CNS); COMPOSTO; SUA COMPOSIçãO FARMACêUTICA; USO E MéTODO PARA TRATAMENTO". A presente invenção refere-se aos ligandos receptores de dopamina e serotonina tendo a fórmula geral (I) onde um de Y^ 1^ e y^ 2^ é N, o qual é unido a Z, e os significados adicionais de Y^ 1^, Y^ 2^, Y^ 3^, Y^ 4^, Z, W, n, m, X, R, e R^ 1^-R^ 12^ são fornecidos nas reivindicações e na descrição. Os compostos da invenção são úteis no tratamento de determinados distúrbios psiquiátricos e neurológicos, por exemplo, esquizofrenia, outras psicoses, distúrbios de ansiedade, tais como, distúrbios de ansiedade generalizada, distúrbio de pânico e distúrbios de compulsividade obsessiva, depressão, agressão, distúrbios cognitivos, efeitos colaterais induzidos por agentes antipsicóticos convencionais, enxaqueca, distúrbio de hiperatividade com déficit de atenção e na melhora do sono.
BR0112286-0A 2000-06-29 2001-06-13 Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (cns); composto; sua composição farmacêutica; uso e método para tratamento BR0112286A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001018 2000-06-29
PCT/DK2001/000407 WO2002000645A1 (en) 2000-06-29 2001-06-13 Indole derivatives useful for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
BR0112286A true BR0112286A (pt) 2003-05-13

Family

ID=8159589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112286-0A BR0112286A (pt) 2000-06-29 2001-06-13 Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (cns); composto; sua composição farmacêutica; uso e método para tratamento

Country Status (23)

Country Link
US (1) US20030232822A1 (pt)
EP (1) EP1299380B1 (pt)
JP (1) JP2004501912A (pt)
KR (1) KR20030011365A (pt)
CN (1) CN1439004A (pt)
AR (1) AR028736A1 (pt)
AT (1) ATE268765T1 (pt)
AU (1) AU2001273882A1 (pt)
BG (1) BG107471A (pt)
BR (1) BR0112286A (pt)
CA (1) CA2414115A1 (pt)
CZ (1) CZ20024192A3 (pt)
DE (1) DE60103761D1 (pt)
EA (1) EA200300084A1 (pt)
HU (1) HUP0300786A2 (pt)
IL (1) IL153254A0 (pt)
IS (1) IS6642A (pt)
MX (1) MXPA02012506A (pt)
NO (1) NO20026029D0 (pt)
PL (1) PL358966A1 (pt)
SK (1) SK1092003A3 (pt)
WO (1) WO2002000645A1 (pt)
ZA (1) ZA200209886B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117577D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
WO2004020437A1 (en) * 2002-08-29 2004-03-11 H. Lundbeck A/S S-(+)-3-{1-[2-(2,3-dihydro-1h-indol-3-yl)ethyl]-3,6-dihydro-2h-pyridin-4-yl}-6-chloro-1h-indole and acid addition salts thereof
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
CN101522197B (zh) * 2006-07-31 2013-12-11 詹森药业有限公司 尾加压素ⅱ受体拮抗剂
SE531698C2 (sv) 2007-07-12 2009-07-07 Respiratorius Ab Nya bronkdilaterande a,b-omättade amider
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020497A1 (en) * 1993-03-01 1994-09-15 Merck Sharp & Dohme Limited Pyrrolo-pyridine derivatives
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives

Also Published As

Publication number Publication date
CN1439004A (zh) 2003-08-27
JP2004501912A (ja) 2004-01-22
NO20026029L (no) 2002-12-16
KR20030011365A (ko) 2003-02-07
DE60103761D1 (de) 2004-07-15
AR028736A1 (es) 2003-05-21
CZ20024192A3 (cs) 2003-04-16
EP1299380B1 (en) 2004-06-09
US20030232822A1 (en) 2003-12-18
EP1299380A1 (en) 2003-04-09
PL358966A1 (en) 2004-08-23
BG107471A (en) 2003-10-31
CA2414115A1 (en) 2002-01-03
WO2002000645A1 (en) 2002-01-03
IS6642A (is) 2002-11-29
HUP0300786A2 (hu) 2003-07-28
SK1092003A3 (en) 2003-05-02
AU2001273882A1 (en) 2002-01-08
MXPA02012506A (es) 2003-04-25
ZA200209886B (en) 2003-12-05
ATE268765T1 (de) 2004-06-15
EA200300084A1 (ru) 2003-06-26
NO20026029D0 (no) 2002-12-16
IL153254A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
BR0114552A (pt) N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia
MX2007014400A (es) Novedosos compuestos heterociclicos como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
NO20032161L (no) Tetrahydrobenzazepinderivater for anvendelse som modulatorer av dopamine D3-reseptor (antipsykotiske midler)
BR0214024A (pt) Derivados de 1,2,4-tiadiazol como moduladores de receptor de melanocortina
BR0012607A (pt) Derivados de n- (indolcarbonil) piperazina
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
MA27715A1 (fr) Nouveaux composes d'arylpiperazinyle
ATE449082T1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
ATE428694T1 (de) N-ä1h-indol-5-ylünaphthalin-1-sulphonamid- derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
BR0311436A (pt) Derivados de 1-(aminoalquil)-3-sulfoni-lindol e -indazol como ligandos da 5-hidroxitriptamina-6
BR0213393A (pt) Derivados de éter alquìlico e de alquilamida ou seus sais, processos para produzir um derivado de éter alquìlico, e, composição farmacêutica
BR0112286A (pt) Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (cns); composto; sua composição farmacêutica; uso e método para tratamento
ATE524451T1 (de) Substituierte n-benzo ädü isoxazol-3-yl-amin- derivative als inhibitoren von mglur5, serotonin- (5-ht) und noradrenalin rezeptoren und deren verwendung zur herstellung von arzneimitteln
BR0112998A (pt) Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamento
BR0314796A (pt) Piperazinas substituìdas heterocìclicas para o tratamento de esquizofrenia
CA2411412A1 (en) Indole derivatives useful for the treatment of cns disorders
PT96084A (pt) Processo para a preparacao de ciclo-hexenos substituidos utilizados como agentes do sistema nervoso central
BR0012575A (pt) Derivados de indol
BRPI0511419A (pt) derivado de lactama de pirazinilmetila
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
BR0111763A (pt) Derivados de indol úteis para o tratamento de distúrbios no sistema nervoso central (cns); composto; composição farmacêutica; uso do composto e método de tratamento

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]